{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:38:58Z","timestamp":1790433538125,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01 HL127661-05"],"award-info":[{"award-number":["2R01 HL127661-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006795","name":"Heart Failure Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ahj.2020.10.064","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T10:33:00Z","timestamp":1603535580000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes\u2014Systematic review and meta-analysis of randomized placebo-controlled trials"],"prefix":"10.1016","volume":"232","author":[{"given":"Husam M.","family":"Salah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhi J.","family":"Al'Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Al-Hawwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Vallurupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Paul","family":"Mounsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ahj.2020.10.064_bb0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.064_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.064_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ahj.2020.10.064_bb0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ahj.2020.10.064_bb0025","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"v, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.10.064_bb0030","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"28","author":"Packer","year":"2020","journal-title":"New England Journal of Medicine Published online August"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.064_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"14","key":"10.1016\/j.ahj.2020.10.064_bb0040","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.064_bb0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus","volume":"138","author":"Karin","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2020.10.064_bb0050","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"W.","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ahj.2020.10.064_bb0055","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.ahj.2020.10.064_bb0060","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"L.","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.10.064_bb0065","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"23","author":"Cannon","year":"2020","journal-title":"New England Journal of Medicine Published online September"},{"key":"10.1016\/j.ahj.2020.10.064_bb0070","volume":"24","author":"Heerspink","year":"2020","journal-title":"Dapagliflozin in patients with chronic kidney disease New England Journal of Medicine Published online September"},{"issue":"2","key":"10.1016\/j.ahj.2020.10.064_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"M. LJ, E. IS, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Christoph","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2020.10.064_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis","volume":"7","author":"Zhang","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"10166","key":"10.1016\/j.ahj.2020.10.064_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.064_bb0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2020.10.064_bb0095","doi-asserted-by":"crossref","unstructured":"Malik AH, Yandrapalli S, Goldberg M, Jain D, Frishman WH, Aronow WS. Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials. Cardiology in Review. 2020;28(3). https:\/\/journals.lww.com\/cardiologyinreview\/Fulltext\/2020\/05000\/Cardiovascular_Outcomes_With_the_Use_of.2.aspx.","DOI":"10.1097\/CRD.0000000000000265"},{"key":"10.1016\/j.ahj.2020.10.064_bb0100","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"30","author":"Zannad","year":"2020","journal-title":"The Lancet Published online August"},{"key":"10.1016\/j.ahj.2020.10.064_bb0105","doi-asserted-by":"crossref","unstructured":"Tamargo J. Sodium-glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments. European cardiology. 2019;14(1):23\u201332. doi:10.15420\/ecr.2018.34.2.","DOI":"10.15420\/ecr.2018.34.2"},{"key":"10.1016\/j.ahj.2020.10.064_bb0110","author":"Griffin","year":"2020","journal-title":"Empagliflozin in heart failure: diuretic and cardio-renal effects Circulation Published online May"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.064_bb0115","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ahj.2020.10.064_bb0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.ahj.2020.10.064_bb0125","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Motoaki","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2020.10.064_bb0130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ahj.2020.10.064_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10741-018-9703-2","article-title":"SGLT2 inhibition and heart failure\u2014current concepts","volume":"23","author":"Custodio","year":"2018","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.ahj.2020.10.064_bb0140","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"Journal of the American Society of Nephrology\u202f: JASN"},{"key":"10.1016\/j.ahj.2020.10.064_bb0145","doi-asserted-by":"crossref","unstructured":"Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clinical science (London, England\u202f: 1979). 2018;132(12):1329\u20131339. doi:https:\/\/doi.org\/10.1042\/CS20171298.","DOI":"10.1042\/CS20171298"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.064_bb0150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.064_bb0155","first-page":"45","article-title":"Risks vs Benefits for SGLT2 Inhibitor Medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Federal practitioner\u202f: for the health care professionals of the VA, DoD, and PHS"},{"issue":"5","key":"10.1016\/j.ahj.2020.10.064_bb0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ahj.2020.10.064_bb0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.ahj.2020.10.064_bb0170","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2020.10.064_bb0175","doi-asserted-by":"crossref","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","article-title":"Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials","volume":"163","author":"Miyashita","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ahj.2020.10.064_bb0180","doi-asserted-by":"crossref","unstructured":"Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes\/metabolism research and reviews. 2017;33(6). doi:https:\/\/doi.org\/10.1002\/dmrr.2903.","DOI":"10.1002\/dmrr.2903"},{"issue":"7","key":"10.1016\/j.ahj.2020.10.064_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3170","article-title":"Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis","volume":"35","author":"Li","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ahj.2020.10.064_bb0190","first-page":"27378","article-title":"Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes","author":"Das","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.ahj.2020.10.064_bb0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"v, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrology, dialysis, transplantation\u202f: official publication of the European Dialysis and Transplant Association - European Renal Association"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320303501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320303501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:03Z","timestamp":1762077483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320303501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"alternative-id":["S0002870320303501"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.064","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes\u2014Systematic review and meta-analysis of randomized placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.10.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}